Lexicon Pharmaceuticals announced that the FDA expects to convene an advisory committee meeting on October 31, 2024, to review Zynquista™ (sotagliflozin) for use as an adjunct to insulin therapy in adults with type 1 diabetes and chronic kidney disease (CKD). The PDUFA goal date for the decision remains December 20, 2024.
The Endocrinologic and Metabolic Drugs Advisory Committee will evaluate the safety and efficacy data submitted by Lexicon to support the approval of sotagliflozin. This drug, if approved, would offer a novel treatment option for patients with type 1 diabetes and co-existing CKD, a population with significant unmet medical needs.
"Lexicon looks forward to the opportunity to share the breadth of evidence that has been generated to support the favorable benefit/risk profile of sotagliflozin for glycemic control in people with type 1 diabetes and CKD," said Dr. Mike Exton, chief executive officer and director of Lexicon Pharmaceuticals.
Sotagliflozin's Potential Impact
Sotagliflozin is a dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2). SGLT2 is responsible for glucose reabsorption in the kidney, while SGLT1 is responsible for glucose absorption in the intestine. By inhibiting both transporters, sotagliflozin reduces blood glucose levels through increased urinary glucose excretion and delayed intestinal glucose absorption. The drug is already marketed as INPEFA® (sotagliflozin) in the United States for heart failure.
Type 1 diabetes is a chronic autoimmune disease characterized by the destruction of insulin-producing beta cells in the pancreas, leading to insulin deficiency and hyperglycemia. CKD is a common complication of type 1 diabetes, affecting approximately 30-40% of patients. The combination of type 1 diabetes and CKD significantly increases the risk of cardiovascular events, kidney failure, and mortality.
Currently, treatment options for type 1 diabetes and CKD are limited, often involving intensive insulin therapy and management of blood pressure and cholesterol. Sotagliflozin represents a potential new approach to improve glycemic control and reduce the risk of adverse outcomes in this high-risk population.
Lexicon's submission to the FDA includes data from clinical trials evaluating the efficacy and safety of sotagliflozin in patients with type 1 diabetes and CKD. The advisory committee will review these data to determine whether the benefits of sotagliflozin outweigh the risks for this indication. The FDA intends to make the background materials available to the public no later than two business days before the meeting.
